Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C codeveloped by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3.4A serine protease. Telaprevir is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to have an effect on or being safe when used for other genotypes of the virus. The standard therapy of pegylated interferon and ribavirin is less effective on genotype 1.

CAS：402957-28-2
中文别名：特拉匹伟;TELAPREVIR;特拉匹伟/VX950;
英文别名：VX-950;Telaprevir;Telaprevir (VX-950);
分子式：C36H53N7O6
分子量：679.849
精确质量：679.406
Psa：179.56
Logp：3.9474

UNII：655M5O3W0U

密度：1.25 g/cm3

用途
治疗丙肝病毒(HCV)感染